Document is current
Any future updates will be listed below
-
Authors
Pu, Xingxiang
Shou, Jiawei
Xiao, Zemin
Chen, Jun
Xiao, Maoliang
Guo, Qunyi
Ma, Zhongxia
Hong, Wei
Wang, Qianzhi
Wang, Yonghui
Li, Jia
Rao, Chuangzhou
Weng, Jie
Lu, Liqin
Wu, Lin
Fang, Yong
-
Funding
Funding for this research was provided by:
Beijing Xisike Clinical Oncology Research Foundation (Y-2019Genecast-024)
Hunan Cancer Hospital Climb plan (ZX2020005-5)
The science and technology innovation Program of Hunan Province (2023SK4024)
The science and technology innovation Program of Hunan Province (2021SK51121)
Hunan Lung Cancer Clinical Medical Research Center (2023SK4024)
Hunan Provincial Natural Science Foundation of China (2021JJ30430)
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 5 March 2025
First Online: 12 May 2025
Declarations
:
: Xingxiang Pu, Jiawei Shou, Zemin Xiao, Jun Chen, Maoliang Xiao, Qunyi Guo, Zhongxia Ma, Wei Hong, Qianzhi Wang, Yonghui Wang, Jia Li, Chuangzhou Rao, Jie Weng, Liqin Lu, Lin Wu, and Yong Fang have nothing to disclose.
: Central approvals for ALTER-L016 and ALTER-L018 trials were obtained from the institutional review boards of leading centers (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine). The study was conducted in accordance with the ethical principles listed in the Declaration of Helsinki. All patients in both trials provided written informed consent.
